Eli Lilly reports up to 23.3% weight loss with EloraTZP

Eli Lilly announced positive results on September 30, 2026, from a 48-week Phase 2b clinical trial evaluating EloraTZP. The investigational therapy combines eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist. The study evaluated 367 adults with obesity or overweight and type 2 diabetes across sites in the United States and Argentina.

Participants receiving EloraTZP achieved an average weight loss of up to 54.1 lbs, or 23.3%, from an average baseline of 232.4 lbs (105.4 kg). In comparison, participants on tirzepatide 15 mg alone lost an average of 34.4 lbs (14.8%), and those on eloralintide alone lost up to 28.6 lbs (12.3%). All combinations met the primary endpoint of percent change in body weight compared with placebo.

The combination also lowered A1C levels by up to an average of 2.9% from an average baseline of 8.1%. By contrast, tirzepatide 15 mg reduced A1C by 2.4%, and eloralintide alone reduced it by up to 1.4%. The data were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy.

The most frequent adverse events were gastrointestinal, generally mild to moderate, and occurred mostly during dose escalation. Treatment discontinuation rates due to adverse events ranged from 10.8% to 27.0% for EloraTZP, compared to 0% to 10.8% for eloralintide, 2.9% for tirzepatide alone, and 16.7% for placebo. Lilly plans to begin Phase 3 trials of an EloraTZP co-formulation in the fourth quarter of 2026.